X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ALEMBIC PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ALEMBIC PHARMA ABBOTT INDIA/
ALEMBIC PHARMA
 
P/E (TTM) x 37.8 18.0 210.0% View Chart
P/BV x 9.8 4.6 213.7% View Chart
Dividend Yield % 0.7 0.7 95.1%  

Financials

 ABBOTT INDIA   ALEMBIC PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
ALEMBIC PHARMA
Mar-18
ABBOTT INDIA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110645 947.1%   
Low Rs3,996470 850.6%   
Sales per share (Unadj.) Rs1,552.2166.1 934.7%  
Earnings per share (Unadj.) Rs188.821.9 862.2%  
Cash flow per share (Unadj.) Rs196.427.5 714.5%  
Dividends per share (Unadj.) Rs55.004.00 1,375.0%  
Dividend yield (eoy) %1.10.7 151.7%  
Book value per share (Unadj.) Rs796.6117.8 676.4%  
Shares outstanding (eoy) m21.25188.52 11.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.4 97.0%   
Avg P/E ratio x26.825.5 105.1%  
P/CF ratio (eoy) x25.720.3 126.9%  
Price / Book Value ratio x6.34.7 134.0%  
Dividend payout %29.118.3 159.5%   
Avg Mkt Cap Rs m107,376105,090 102.2%   
No. of employees `0003.3NA-   
Total wages/salary Rs m3,9376,228 63.2%   
Avg. sales/employee Rs Th9,929.3NM-  
Avg. wages/employee Rs Th1,185.1NM-  
Avg. net profit/employee Rs Th1,207.7NM-  
INCOME DATA
Net Sales Rs m32,98531,308 105.4%  
Other income Rs m1,17070 1,664.2%   
Total revenues Rs m34,15531,378 108.8%   
Gross profit Rs m5,2456,431 81.6%  
Depreciation Rs m1621,055 15.4%   
Interest Rs m3834 112.4%   
Profit before tax Rs m6,2155,413 114.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2031,204 183.0%   
Profit after tax Rs m4,0124,128 97.2%  
Gross profit margin %15.920.5 77.4%  
Effective tax rate %35.422.2 159.4%   
Net profit margin %12.213.2 92.2%  
BALANCE SHEET DATA
Current assets Rs m22,65518,247 124.2%   
Current liabilities Rs m6,68111,235 59.5%   
Net working cap to sales %48.422.4 216.2%  
Current ratio x3.41.6 208.8%  
Inventory Days Days6586 75.7%  
Debtors Days Days2961 47.5%  
Net fixed assets Rs m83520,035 4.2%   
Share capital Rs m213377 56.4%   
"Free" reserves Rs m16,71521,824 76.6%   
Net worth Rs m16,92822,201 76.2%   
Long term debt Rs m05,000 0.0%   
Total assets Rs m24,16239,411 61.3%  
Interest coverage x163.7160.2 102.2%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.40.8 171.8%   
Return on assets %16.810.6 158.7%  
Return on equity %23.718.6 127.5%  
Return on capital %36.919.7 187.3%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m36914,722 2.5%   
Fx outflow Rs m3,8077,026 54.2%   
Net fx Rs m-3,4387,696 -44.7%   
CASH FLOW
From Operations Rs m1,5273,124 48.9%  
From Investments Rs m-2,148-8,844 24.3%  
From Financial Activity Rs m-1,0245,026 -20.4%  
Net Cashflow Rs m-1,646-693 237.4%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 2.9 272.4%  
FIIs % 0.1 9.1 1.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 13.9 123.0%  
Shareholders   18,270 49,328 37.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 135 Points Lower; Realty and Telecom Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

A 90% Chance of Auto Stocks Moving Up This April(Profit Hunter)

Apr 5, 2019

The Auto index ended on a positive note in the month of April in 9 out of last 10 years. This Auto stock is best placed to benefit from the upswing in this sector.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Apr 18, 2019 03:37 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS